Last updated: August 28, 2026
Brimonidine tartrate and timolol maleate is a fixed-dose ophthalmic combination marketed in the United States as Combigan. The product treats elevated intraocular pressure in patients with glaucoma or ocular hypertension. Its commercial profile has shifted from branded growth to generic price competition following loss of meaningful market exclusivity. The underlying glaucoma market remains durable, but the combination has limited differentiation, no biologic exclusivity barrier, and declining branded pricing power.
What is brimonidine tartrate and timolol maleate used for?
Brimonidine tartrate/timolol maleate ophthalmic solution combines two pressure-lowering mechanisms:
- Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow.
- Timolol maleate is a beta-adrenergic blocker that reduces aqueous humor production.
The U.S. product is Combigan ophthalmic solution, containing brimonidine tartrate 0.2% and timolol maleate equivalent to timolol 0.5%. It is dosed as one drop in the affected eye or eyes twice daily. The product is indicated when additional intraocular pressure reduction is required beyond monotherapy with either component.[1]
The combination is used primarily in:
- Primary open-angle glaucoma
- Ocular hypertension
- Patients inadequately controlled on a single topical agent
- Patients seeking fewer daily administrations than separate brimonidine and timolol bottles
The principal commercial limitation is that both active ingredients are mature generic drugs. The fixed-dose product offers convenience and adherence benefits, but those benefits are difficult to protect once generic combination products enter the market.
What is the FDA regulatory status of Combigan?
Combigan was approved by the U.S. Food and Drug Administration under NDA 021398. Allergan developed and commercialized the product before its eye-care business became part of AbbVie through the 2020 acquisition of Allergan.[2][3]
| Regulatory item |
Status |
| Active ingredients |
Brimonidine tartrate and timolol maleate |
| Dosage form |
Sterile ophthalmic solution |
| Strength |
Brimonidine 0.2% / timolol 0.5% |
| U.S. brand |
Combigan |
| FDA application |
NDA 021398 |
| Original sponsor |
Allergan |
| Current corporate owner |
AbbVie |
| Therapeutic area |
Ophthalmology, glaucoma and ocular hypertension |
| Administration |
Topical ophthalmic, generally twice daily |
| Regulatory pathway for competitors |
ANDA, subject to pharmaceutical equivalence and bioequivalence requirements |
The product is not a biologic. Biosimilar litigation and biologic interchangeability rules do not apply. Competitive entry occurs through abbreviated new drug applications, authorized generics, branded generics, and other ophthalmic products.
What patents protect brimonidine tartrate and timolol maleate?
The active ingredients have long-established composition-of-matter histories and do not provide meaningful modern exclusivity for the fixed-dose combination. The relevant patent value has historically centered on the combination formulation, dosing regimen, ophthalmic vehicle, preservative system, and manufacturing or packaging characteristics.
The Orange Book is the controlling source for patents and regulatory exclusivity listed against NDA 021398. Patent coverage can change through expiration, delisting, pediatric extensions, litigation outcomes, and regulatory updates. The commercial importance of Combigan’s patent estate has declined because generic manufacturers have obtained FDA approval for equivalent brimonidine/timolol products.[4]
What formulations are protected by the product’s patent estate?
Potentially relevant formulation claims in this product category can address:
- The fixed combination of brimonidine and timolol
- Concentration ranges for each active ingredient
- Ophthalmic pH and osmolality
- Preservative systems
- Stabilization of brimonidine in aqueous solution
- Dosing frequency
- Container and dropper configurations
- Compatibility of the formulation with multi-dose packaging
These claims are narrower than composition-of-matter patents covering a new chemical entity. A generic applicant may challenge listed patents through a Paragraph IV certification, design around nonessential claim elements, or wait for patent expiration.
The principal barrier is regulatory and manufacturing execution rather than active-ingredient discovery. Ophthalmic solutions must meet requirements for sterility, particulate control, container-closure integrity, preservative performance, stability, and dose delivery. Those requirements can delay entry, but they rarely sustain premium pricing after several approved generics are available.
When did brimonidine/timolol lose exclusivity?
The product’s commercial exclusivity has effectively ended. Combigan has been on the U.S. market for more than a decade, and generic versions of brimonidine tartrate/timolol maleate ophthalmic solution have received FDA approval.
FDA approval of an ANDA does not always produce immediate commercial launch. Timing depends on:
- Patent certifications and litigation.
- Any 30-month stay triggered by patent litigation.
- Settlement terms between the brand and generic applicant.
- Manufacturing readiness.
- Distributor and pharmacy contracting.
- State substitution rules and payer formulary placement.
The practical loss of exclusivity therefore occurs in stages:
| Stage |
Commercial effect |
| Brand-only period |
High price and control of prescribing |
| First generic approval |
Lower expected net price and launch-option value |
| First generic launch |
Rapid share migration in price-sensitive channels |
| Multiple generic launches |
Commodity pricing and lower manufacturer margins |
| Mature generic market |
Volume may remain stable while revenue per unit declines |
Combigan did not have the exclusivity economics of a newly approved glaucoma drug. Its market protection depended on formulation and product-specific rights rather than a long remaining period of new chemical entity exclusivity.
Which companies are challenging or competing with Combigan?
Competition comes from both generic versions of the same fixed combination and alternative glaucoma regimens.
Generic manufacturers
FDA-approved or commercially active generic competition has included ophthalmic manufacturers such as Teva, Mylan or Viatris, Sandoz, Apotex, and other ANDA holders depending on market and time period. Supplier participation can vary by country and by the status of individual ANDAs.
The most important competitive characteristics are:
- FDA approval of the same strengths
- Ability to manufacture sterile ophthalmic solutions at scale
- Wholesale acquisition cost
- Contracting with pharmacy benefit managers and wholesalers
- Supply reliability
- Preservative and packaging equivalence
- Acceptance by ophthalmologists and formularies
Generic manufacturers generally compete on price and availability rather than clinical differentiation.
Therapeutic substitutes
Combigan competes with:
- Brimonidine monotherapy
- Timolol monotherapy
- Dorzolamide/timolol fixed combination, marketed as Cosopt and generics
- Brinzolamide/brimonidine fixed combination, marketed as Simbrinza
- Latanoprost/timolol fixed combination, including Xalacom in some markets
- Prostaglandin analogs such as latanoprost, bimatoprost, and travoprost
- Rho kinase inhibitors such as netarsudil
- Selective laser trabeculoplasty and surgical interventions
Prostaglandin analogs are often preferred as first-line therapy because of effective intraocular pressure reduction and once-daily dosing. Brimonidine/timolol is more commonly positioned as add-on therapy or as a substitute for two separate agents.
How strong is the patent estate for brimonidine/timolol?
The patent estate is commercially weak to moderate today.
It is weak in relation to:
- Active-ingredient exclusivity
- Generic substitution risk
- Availability of equivalent ophthalmic dosage forms
- Limited ability to preserve premium pricing after entry
It is stronger in relation to:
- Complex sterile manufacturing
- Stability and preservative requirements
- Specific formulation parameters
- Potential device or container-closure claims
- Regulatory execution and supply-chain qualification
Patent strength should be separated from manufacturing difficulty. A technically demanding ophthalmic product can still experience rapid price erosion if multiple manufacturers qualify comparable products. The highest-value rights would be claims that are difficult to design around and are listed in the Orange Book with enforceable remaining life. Generic approval and market presence indicate that any remaining patent barriers have not prevented competitive entry.
What is the Orange Book status of Combigan?
Combigan is an NDA product that has historically been subject to Orange Book patent listings. The FDA Orange Book identifies patents and regulatory exclusivity associated with approved drug applications, but it does not determine whether a patent is valid or infringed.[4]
For commercial diligence, the relevant questions are:
- Which patents remain listed against NDA 021398?
- Have all listed patents expired?
- Did any ANDA applicant file a Paragraph IV certification?
- Was litigation filed within the statutory period?
- Was a 30-month stay triggered?
- Did the parties sign a launch settlement?
- Are any pediatric or other exclusivities still active?
Because generic products are approved and available, the remaining Orange Book record has limited ability to block the entire market. It may still affect individual launch dates, product labeling, or the timing of a particular ANDA holder’s entry.
What Paragraph IV challenges and litigation affect the product?
Paragraph IV litigation is the principal U.S. mechanism for challenging listed patents before expiration. An ANDA applicant certifies that the listed patent is invalid, unenforceable, or will not be infringed. The brand holder can sue within 45 days, triggering a statutory approval stay of up to 30 months under the Hatch-Waxman framework.[5]
For Combigan, the commercially relevant litigation question is whether any historic patent dispute delayed generic entry and whether settlements permitted an agreed launch date. A litigation record involving one ANDA holder does not necessarily prevent entry by other applicants after the relevant patent or settlement barrier expires.
The available public regulatory record supports a conclusion of completed or substantially completed generic entry rather than an active brand defense capable of preserving market exclusivity. Current investment analysis should focus on generic pricing, supply concentration, and reimbursement rather than on the probability of a new patent-driven exclusion period.
What is the financial trajectory for brimonidine/timolol?
AbbVie does not generally report Combigan revenue as a separate public line item. The product is included within broader pharmaceutical or eye-care reporting, making a precise standalone revenue series unavailable from company filings.[3]
The likely financial trajectory has four phases:
| Period |
Revenue pattern |
Margin pattern |
| Initial branded adoption |
Prescription growth from fixed-dose convenience |
High branded gross margin |
| Mature brand period |
Stable or modestly declining volume |
Increasing payer pressure |
| Generic entry |
Sharp decline in branded unit share and net price |
Material margin compression |
| Mature generic period |
Lower revenue per unit, potentially stable aggregate demand |
Low-to-moderate commodity margins |
The market retains recurring demand because glaucoma is chronic and treatment is typically long term. That recurring demand supports volume but does not protect price. Once multiple generic suppliers enter, payer formularies and pharmacy substitution redirect demand toward the lowest-cost equivalent.
For AbbVie, the financial exposure is likely modest relative to major immunology, oncology, and aesthetics franchises. The product’s value is more relevant to the ophthalmology portfolio and to the profitability of established eye-care products than to consolidated corporate earnings.
What generic launch scenarios exist?
Single-generic scenario
A single generic supplier can preserve comparatively strong pricing, especially if it has reliable supply and limited competition. The brand may retain a meaningful share among physicians who prefer the original product or among patients experiencing tolerability differences.
Multi-generic scenario
Multiple suppliers typically produce faster price erosion. Pharmacy substitution increases, while formulary managers gain leverage. The brand may respond through rebates, patient support, authorized-generic arrangements, or channel-specific contracting.
Supply-constrained scenario
Ophthalmic manufacturing failures, sterile facility inspections, component shortages, or preservative shortages can temporarily improve pricing for suppliers with available inventory. This is a supply event rather than durable patent protection.
Formulation-differentiation scenario
Preservative-free or improved-delivery versions could command a premium if supported by clinical evidence, payer coverage, and physician adoption. Such products would compete as differentiated follow-on formulations rather than as conventional generic substitutes.
How does brimonidine/timolol compare with competing glaucoma combinations?
| Product category |
Main advantage |
Main commercial risk |
| Brimonidine/timolol |
Two mechanisms in one bottle; twice-daily dosing |
Generic erosion and ocular tolerability |
| Dorzolamide/timolol |
Established fixed combination and broad generic availability |
Three-times-daily use in some regimens; generic pricing |
| Brinzolamide/brimonidine |
Prostaglandin-sparing combination without a beta blocker |
Higher branded cost and suspension formulation |
| Latanoprost/timolol |
Once-daily prostaglandin/beta-blocker combination |
Generic competition and prostaglandin side effects |
| Prostaglandin monotherapy |
Strong efficacy and convenient dosing |
Hyperemia, eyelash growth, iris pigmentation |
| Rho kinase inhibitor therapy |
Newer mechanism and differentiated positioning |
Higher cost and tolerability concerns |
Brimonidine/timolol is best positioned where clinicians need incremental pressure reduction and want to avoid prescribing two separate bottles. It is less advantaged when once-daily prostaglandin therapy is sufficient or when patients cannot tolerate brimonidine or beta blockers.
What geographic markets remain attractive?
The United States is the most mature and price-competitive market. Generic penetration and payer substitution reduce brand opportunity, while chronic glaucoma prevalence supports stable demand.
Europe and other developed markets also have mature generic competition, though pricing, reimbursement, reference-pricing systems, and substitution rules differ by country. In emerging markets, volume growth may be stronger because diagnosis and treatment access are expanding. Revenue per unit is typically lower, and local manufacturing or tender participation can determine market access.
Geographic opportunity is therefore volume-led rather than exclusivity-led. The strongest commercial positions belong to manufacturers with local regulatory approvals, dependable sterile supply, and low-cost distribution.
What manufacturing and intellectual-property barriers remain?
The principal barriers are operational:
- Sterile filling and aseptic processing
- Validated preservative effectiveness
- Container-closure integrity
- Chemical stability of brimonidine and timolol
- Consistent ophthalmic drop size
- Control of particulate matter
- Global pharmacopoeial compliance
- Reliable supply of bottles, droppers, and preservatives
These barriers can limit the number of active suppliers and create temporary shortages. They do not create the same long-term protection as a composition-of-matter patent.
Key Takeaways
- Brimonidine tartrate/timolol maleate is a mature fixed-dose glaucoma combination marketed in the U.S. as Combigan.
- The product is approved under NDA 021398 and is owned by AbbVie following the Allergan acquisition.
- Active-ingredient patents no longer provide meaningful exclusivity.
- Generic competition has materially reduced the product’s branded pricing power.
- The product remains clinically relevant because glaucoma treatment is chronic and fixed-dose combinations can reduce treatment burden.
- Standalone Combigan revenue is not separately disclosed in AbbVie’s public financial reporting.
- Current value is concentrated in manufacturing reliability, supply availability, contracting, and geographic execution.
- Patent litigation and Paragraph IV risk are secondary to generic price erosion in the mature U.S. market.
- Biosimilar risk does not apply because the product is a small-molecule ophthalmic drug, not a biologic.
- New commercial upside would require a differentiated formulation, preservative-free presentation, improved delivery system, or expansion into underpenetrated markets.
FAQs
Is Combigan still under patent protection?
Combigan’s meaningful market exclusivity has ended as generic brimonidine/timolol products have received FDA approval. The current Orange Book record should be reviewed for any remaining listed patents or application-specific constraints.
Can brimonidine/timolol generics be automatically substituted for Combigan?
FDA-approved generics are therapeutically equivalent when designated as such, but substitution is governed by state pharmacy laws, payer rules, product availability, and prescription instructions.
Does Combigan have biosimilar competition?
No. Combigan is a small-molecule ophthalmic solution. Competitors enter through the ANDA generic-drug pathway rather than the biosimilar pathway.
What is the main side-effect risk affecting commercial demand?
Brimonidine can cause ocular allergy, conjunctival hyperemia, and fatigue or systemic effects in susceptible patients. Timolol can cause cardiovascular and respiratory adverse effects, making beta-blocker contraindications commercially relevant.[1]
Could a preservative-free brimonidine/timolol product regain premium pricing?
A preservative-free or delivery-enhanced product could support premium positioning if it demonstrates tolerability, adherence, or clinical advantages and receives favorable reimbursement. Patent protection alone would not guarantee commercial uptake.
References
- U.S. Food and Drug Administration. (2023). Combigan (brimonidine tartrate and timolol maleate ophthalmic solution) prescribing information.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Combigan, NDA 021398.
- AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417.
